The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

PART 2 U.K. Amendment of Part 1 (General)

Definitions in relation to advanced therapy medicinal products U.K.

4.  After regulation 2, insert—

“Definition of advanced therapy medicinal product etc.

2A.— (1) In these Regulations, [F1 in their application to products for sale or supply in Great Britain only,] “advanced therapy medicinal product” means any of the following products—

(a) a gene therapy medicinal product;

(b) a somatic cell therapy medicinal product; or

(c) a tissue engineered product.

(2) A “gene therapy medicinal product” is a biological medicinal product which has the following characteristics—

(a) it contains an active substance which contains or consists of a recombinant nucleic acid used in or administered to human beings with a view to regulating, repairing, replacing, adding or deleting a genetic sequence; and

(b) its therapeutic, prophylactic or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains, or to the product of genetic expression of this sequence.

(3) A vaccine against infectious diseases is not to be treated as a gene therapy medicinal product.

(4) A “somatic cell medicinal product” is a medicinal product which has the following characteristics—

(a) it contains or consists of cells or tissues that—

(i) have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered, or

(ii) are not intended to be used for the same essential function in the recipient as in the donor; and

(b) it is presented as having properties for, or is used in or administered to human beings with a view to, treating, preventing or diagnosing a disease through the pharmacological, immunological or metabolic action of its cells or tissues.

(5) A “tissue engineered product” is a medicinal product which—

(a) contains or consists of engineered cells or tissues; and

(b) is presented as having properties for, or is used in or administered to human beings with a view to, regenerating, repairing or replacing a human tissue.

(6) A tissue engineered product may contain—

(a) cells or tissues of human or animal origin;

(b) viable or non-viable cells or tissues; and

(c) additional substances, including cellular products, bio-molecules, biomaterials, chemical substances, scaffolds or matrices.

(7) A product is not a tissue engineered product if it—

(a) contains or consists exclusively of non-viable human or animal cells or tissues;

(b) does not contain any viable cells or tissues; and

(c) does not act principally by pharmacological, immunological or metabolic action.

(8) Cells or tissues are engineered if they—

(a) have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved; or

(b) are not intended to be used for the same essential function in the recipient as in the donor.

(9) The following manipulations are not substantial manipulations for the purposes of paragraphs (4)(a) and (8)(a)—

(a) cutting;

(b) grinding;

(c) shaping;

(d) centrifugation;

(e) soaking in antibiotic or antimicrobial solutions;

(f) sterilisation;

(g) irradiation;

(h) cell separation, concentration or purification;

(i) filtering;

(j) lyophilisation;

(k) freezing;

(l) cryopreservation; and

(m) vitrification.

(10) In these Regulations, [F1 in their application to products for sale or supply in Great Britain only,] “combined advanced therapy medicinal product” means an advanced therapy medicinal product—

(a) which incorporates, as an integral part of the product, one or more medical devices or one or more active implantable medical devices; and

(b) the cellular part of which—

(i) contains viable cells or tissues; or

(ii) contains non-viable cells or tissues which are liable to act upon the human body with action that can be considered as primary to that of the medical devices.

(11) Where an advanced therapy medicinal product contains viable cells or tissues, the pharmacological, immunological or metabolic action of those cells or tissues is to be treated as the principal mode of action of the product.

(12) An advanced therapy medicinal product containing both autologous and allogeneic cells or tissues is to be treated as being for allogeneic use.

(13) A product which falls within the definition of a tissue engineered product and within the definition of a somatic cell therapy medicinal product is to be treated as a tissue engineered product.

(14) A product which falls within the definition of—

(a) a somatic cell therapy medicinal product or a tissue engineered product; and

(b) a gene therapy medicinal product,

is to be treated as a gene therapy medicinal product.”.

Textual Amendments

F1 Words in reg. 4 inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 1

Commencement Information

I1 Reg. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 3 (scope of Regulations: special provisions) U.K.

5.—(1) Regulation 3 is amended as follows.

(2) In paragraph (12)(d)—

(a) in paragraph (i) insert “ UK ” before “marketing authorisation”;

[F2 (b) after paragraph (i) insert—

“(ia) the EU marketing authorisation,”.]

(3) In paragraph (15)—

(a) in sub-paragraph (a) insert “ UK ” before “marketing authorisation”; and

[F3 (b) after paragraph (i) insert—

“(aa) an EU marketing authorisation;”.]

Textual Amendments

F2 Reg. 5(2)(b) substituted for reg. 5(2)(b)(c) (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 2(a)

F3 Reg. 5(3)(b) substituted for reg. 5(3)(b)(c) (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 2(b)

Commencement Information

I2 Reg. 5 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 4 (special provision for pharmacies etc) U.K.

[F4 6.   In regulation 4—

(a) in paragraph (4)(d)—

(i) in paragraph (i) insert “UK” before “marketing authorisation”;

(ii) after paragraph (i) insert—

“(ia) the EU marketing authorisation,”;

(b) in paragraph (6) for “269 (offences relating to packaging and package leaflets: other persons)” substitute “269 (offences relating to packaging and package leaflets in Great Britain: other persons), 269A (offences relating to packaging and package leaflets in Northern Ireland: other persons)”.]

Textual Amendments

F4 Reg. 6 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 3

Commencement Information

I3 Reg. 6 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of regulation 5 (classification of medicinal products) U.K.

7.—(1) Regulation 5 is amended as follows.

[F5 (2) In paragraph (1)(b), before “a product that” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”.]

(3) In paragraph (2)—

F6 (a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

[F7 (b) in sub-paragraph (d), before “an Article 126a” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”.]

(4) In paragraph (3)—

[F8 (a) in sub-paragraph (b), before “a medicinal product” insert “in the case of a medicinal product for sale or supply in Northern Ireland, ”;]

F9 (b) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(5) In paragraph (4), [F10 in sub-paragraph (b), before “an Article” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”.]

(6) In paragraph (5)—

[F11 (a) in sub-paragraph (b), before “a product that” insert “in the case of a medicinal product for sale or supply in Northern Ireland,”; and]

F12 (b) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

F5 Reg. 7(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(a)

F6 Reg. 7(3)(a) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(b)(i)

F7 Reg. 7(3)(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(b)(ii)

F8 Reg. 7(4)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(c)(i)

F9 Reg. 7(4)(b) omitted (31.12.2020) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(c)(ii)

F10 Words in reg. 7(5) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(d)

F11 Reg. 7(6)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(e)(i)

F12 Reg. 7(6)(b) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 4(e)(ii)

Commencement Information

I4 Reg. 7 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Amendment of Schedule 1 (further provisions for classification of medicinal products) U.K.

[F13 8.   In Schedule 1—

(a) in paragraph 1—

(i) in sub-paragraph (b), insert “UK” before “marketing authorisation”;

(ii) in sub-paragraphs (e)(i), (f)(i) and (g)(i), for “marketing authorisation” substitute “UK marketing authorisation, EU marketing authorisation, Article 126a authorisation or parallel import licence”; and

(b) in paragraph 4, for “marketing authorisation” substitute “UK marketing authorisation, EU marketing authorisation, Article 126a authorisation, parallel import licence”.]

Textual Amendments

F13 Reg. 8 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 5

Prospective

Amendment of regulation 6 (the licensing authority and the Ministers) U.K.

F14 9.  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Textual Amendments

F14 Reg. 9 omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 6

Amendment of regulation 8 (general interpretation) U.K.

10.—(1) Regulation 8 M1 is amended as follows.

(2) In paragraph (1), at the appropriate places, insert—

““active implantable medical device”—

(a) has the meaning given in regulation 2 of the Medical Devices Regulations 2002 M2 ; or

(b) to the extent necessary for the practical application of that definition, also or instead has the meaning given in regulation 137 of those Regulations M3 ;”;

““agreed paediatric investigation plan” means a paediatric investigation plan which the licensing authority has agreed in accordance with regulation 50B;”;

““Annex I to the 2001 Directive” means [F15 , in relation to UKMA(GB),] Annex I to the 2001 Directive, as modified in accordance with Schedule 8B;”;

““approved country for batch testing list” means the list published by the licensing authority under paragraph 14(3) of Schedule 7 (obligations of qualified persons) and “approved country for batch testing” means a country included in that list;”;

““approved country for import list” means the list published by the licensing authority under regulation 18A (approved country for import) and “approved country for import” means a country included in that list;”;

““the Committee for Medicinal Products for Human Use” means the committee established under Article 5(1) of Regulation (EC) No 726/2004;”;

““conditional marketing authorisation” means a [F16 UKMA(GB)] granted under regulation 49(1)(a) in accordance with regulation 58F;”;

““country” means a country or territory;”;

““Directive 2001/18/EC” means Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC – Commission Declaration M4 ;”;

[F17 ““EU agreed paediatric investigation plan” means a paediatric investigation plan agreed in accordance with the Paediatric Regulation;”];

““EU Exit Regulations” means the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019;”;

““medical device”—

(a) has the meaning given in regulation 2 of the Medical Devices Regulations 2002; or

(b) to the extent necessary for the practical application of that definition, also or instead has the meaning given in regulation 69 of those Regulations M5 ;”;

[F17 ““nursing home” has the meaning given by article 11 of the Health and Personal Social Services (Quality, Improvement and Regulation) (Northern Ireland) Order 2003; ”; and]

““orphan criteria” means the criteria listed in regulation 50G(2);”;

““orphan marketing authorisation” means a UK marketing authorisation granted under regulation 49(1)(a) in accordance with regulation 58C;”;

““Orphan Regulation” means Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products M6 as it has effect in EU law;”;

““paediatric indication” means a term of a UK marketing authorisation enabling the medicinal product to which the authorisation relates to be used by or administered to persons under the age of 18 years;”;

““paediatric population” means that part of the population consisting of persons under the age of 18 years;”;

[F17 ““parallel import licence” has the meaning given in regulation 48(2);”];

[F17 ““qualifying Northern Ireland goods” has the same meaning that it has in the European Union (Withdrawal) Act 2018, including any meaning defined for the purposes of that Act from time to time by regulations made under the power conferred by section 8C(6) of that Act;”];

““supplementary protection certificate” has the meaning given in section 128B(2) of the Patents Act 1977 M7 ;”; and

[F17 ““under the unfettered access route” means an application for—

(a) a UKMA(GB) under reduced or alternative requirements specified in Part 5 (as referred to in regulation 49(1A));

(b) a COR(GB) under reduced or alternative requirements specified in Part 6 (as referred to in regulation 103(1A));

(c) a THR(GB) under reduced or alternative requirements specified in Part 7 (as referred to in regulation 127(1A));”].

““variation to the terms of a UK marketing authorisation” means any change to—

(a) the information provided in accordance with regulations 50 to 57 and Schedule 8; or

(b) the terms of the decision granting the UK marketing authorisation, including the summary of the product characteristics and any conditions, obligations, or restrictions affecting that UK marketing authorisation, or changes to the labelling or the package leaflet connected with changes to the summary of the product characteristics,

and “vary” and “variation” in relation to a UK marketing authorisation are to be construed accordingly;.”.

[F17 ““withdrawal agreement” has the meaning given in section 39 of the European Union (Withdrawal Agreement) Act 2020;”];

(3) In paragraph (1), amend or substitute (as the case may be) the following definitions—

[F18 (za) in the definition of “advanced therapy medicinal product”, after “means” insert “, in the case of a medicinal product for sale or supply by the holder of a UKMA(NI) or UKMA(UK),”;

(zb) in the definition of “certificate of registration”, after “these Regulations” insert—

“and—

(a)

“COR(UK)” means such a certificate in force in the whole United Kingdom;

(b)

“COR(GB)” means such a certificate in force in Great Britain only;

(c)

“COR(NI)” means such a certificate in force in Northern Ireland only;”;]

[F19 (a) for the definition of “the Good Manufacturing Practice Directive” substitute—

““the Good Manufacturing Practice Directive” means—

(a)

in the case of a medicinal product manufactured or assembled in, or imported into, Great Britain—

(i)

Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice for medicinal products for human use and for investigational medicinal products for human use, as modified by Schedule 2A, or

(ii)

if Regulations have been made under the powers in regulation B17(1), and have come into force, those Regulations;

(b)

in the case of a medicinal product manufactured or assembled in, or imported into, Northern Ireland, Commission Directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice for medicinal products for human use and for investigational medicinal products for human use;”;]

(b) in the definition of “homoeopathic medicinal product”, in paragraph (b), for “in any pharmacopoeia used officially in an EEA State” [F20 substitute—

(i) in relation to a certificate of registration or marketing authorisation for a national homoeopathic product in force in Great Britain only, the British Pharmacopoeia, or in an pharmacopoeia used officially in an country that is included in a list published by the licensing authority for this purpose;

(ii) in relation to a certificate of registration or marketing authorisation for a national homoeopathic product in force in the whole United Kingdom or in Northern Ireland only, in the British Pharmacopoeia or in any pharmacopoeia used officially in an EEA State;]

(c) in the definition of “import”M8 , insert at the end “ and “imported” is to be construed accordingly ”;

F21 (d) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(e) in the definition of “pharmacovigilance system”, “pharmacovigilance system master file” and “post-authorisation safety study”, [F22 for “marketing authorisation” substitute “UK marketing authorisation, EU marketing authorisation”]

(f) in the definition of “post-authorisation efficacy study”, insert “ UK ” before “marketing authorisation”;

(g) at the end of the definition of “Regulation (EC) No 726/2004”, insert “ , as it has effect in EU law ”;

(h) at the end of the definition of “Regulation (EC) No 1234/2008”, insert “ , as it has effect in EU law ”;

(i) in the definition of “special medicinal product” for “an EEA State” substitute “ a country ”;

[F23 (j) in the definition of “traditional herbal registration”, after “these Regulations” insert—

“and—

(a)

“THR(UK)” means such a registration in force in the whole United Kingdom;

(b)

“THR(GB)” means such a registration in force in Great Britain only;

(c)

“THR(NI)” means such a registration in force in Northern Ireland only;”;]

[F24 (k) for the definition of “UK marketing authorisation” substitute—

““UK marketing authorisation” means a marketing authorisation granted by the licensing authority under Part 5 of these Regulations or Chapter 4 of Title III to the 2001 Directive (mutual recognition and decentralised procedure) and—

(a)

“UKMA(UK)” means such an authorisation in force in the whole United Kingdom;

(b)

“UKMA(GB)” means such an authorisation in force in Great Britain only;

(c)

“UKMA(NI)” means such an authorisation in force in Northern Ireland only.”;]

(4) In paragraph (1), omit the following definitions—

F25 (i) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F26 (ii) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(iii) “care home” M9 ,

F27 (iv) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(v) “Directive 2002/98/EC”,

(vi) “Directive 2004/23/EC”,

F28 (vii) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F29 (viii) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F30 (ix) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F31 (x) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F32 (xi) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F33 (xii) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(xiii) “third country”.

(5) In paragraph (5)(a) insert “ UK ” before “marketing authorisation”.

(6) In paragraph (6)(a)—

(a) insert “ UK ” before “marketing authorisation”; and

(b) for “or 60(1)” substitute “ , 60(1) or 60A ”.

(7) In paragraph (8) M10 , for “References” substitute “ Subject to regulation C17(6), references ”.

[F34 (8) After paragraph (8) insert—

“(9) Unless otherwise provided, any provision of an EU Regulation made applicable to a UKMA(NI), COR(NI) or THR(NI) by virtue of Article 5(4) of, and Annex 2 to, the Protocol on Ireland/Northern Ireland in the EU withdrawal agreement applies equally in respect of a UKMA(UK), COR(UK) or THR(UK).”.]

Textual Amendments

F15 Words in reg. 10(2) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(a)(i)(aa)

F16 Word in reg. 10(2) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(a)(i)(bb)

F17 Words in reg. 10(2) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(a)(ii)

F18 Reg. 10(3)(za)(zb) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(b)(i)

F19 Reg. 10(3)(a) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(b)(ii)

F20 Words in reg. 10(3)(b) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(b)(iii)

F21 Reg. 10(3)(d) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(b)(iv)

F22 Words in reg. 10(3)(e) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(b)(v)

F23 Reg. 10(3)(j) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(b)(vi)

F24 Reg. 10(3)(k) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(b)(vii)

F25 Reg. 10(4)(i) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F26 Reg. 10(4)(ii) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F27 Reg. 10(4)(iv) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F28 Reg. 10(4)(vii) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F29 Reg. 10(4)(viii) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F30 Reg. 10(4)(ix) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F31 Reg. 10(4)(x) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F32 Reg. 10(4)(xi) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F33 Reg. 10(4)(xii) omitted (31.12.2020 immediately before IP completion day) by virtue of The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(c)

F34 Reg. 10(8) inserted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 7(d)

Commencement Information

I5 Reg. 10 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Marginal Citations

M1 Regulation 8 was amended by S.I. 2013/1855 and 2593, 2015/1503, 2016/186, 190 and 696, 2017/715, 2018/199 and 2019/62.

M2 S.I. 2002/618. It was amended by S.I. 2008/2936.

M3 Regulation 137 is inserted by the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019.

M4 OJ No. L 106, 17.4.2001, p. 1, as last amended by Commission Directive (EU) 2018/350.

M5 Regulation 69 is inserted by the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019.

M6 OJ No. L 018, 22.01.2000, p. 1.

M7 1977 c. 37. Section 128B was inserted by S.I. 2007/3293 and subsection (2) was amended by S.I.2014/2411.

M8 The definition of “import” was inserted by S.I. 2013/1855.

M9 The definition of “care home” was inserted by S.I. 2019/62.

M10 Paragraph (8) was inserted by S.I. 2013/1855.

Insertion of Schedule 8B (modifications of Annex I to the 2001 Directive) U.K.

11.  Schedule 2 inserts a new Schedule 8B after Schedule 8A.

Commencement Information

I6 Reg. 11 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Insertion of Schedule 2A (modifications of Commission Directive 2003/94/EC) U.K.

12.  Schedule 3 inserts a new Schedule 2A after Schedule 2.

Commencement Information

I7 Reg. 12 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1